Understanding Asia’s success as a rare disease clinical trial location
There may be as many as 7,000 rare diseases affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 25 to 30 million people affected in the US while over 45 million people may be suffering from a rare condition in Asia, with 20 million in China alone.
This webinar will look at Asia’s rare disease clinical trial landscape, and China’s increasing popularity as a clinical trial location, to understand the regional advantages on offer. Our panel will discuss their first-hand experiences and insights working on range of rare disease programs from a clinical trial operations perspective.
This is a must watch webinar to understand the challenges and critical program strategies that need to be considered to support accelerating your clinical program development in the rare disease space.
Presented by
Shahana Hoque-Ali,
Project Manager
Shahana has prosperous experiences in clinical trial industry with about 8 years in project management in well-known multinational pharmaceutical companies. Shahana has expanded her knowledge in various therapeutic areas and indications, such as dermatology (Glabella Lines), neurology (Cervical Dystonia, adult & paediatric upper-limb Spasticity, adult & paediatric lower-limb Spasticity, Alzheimer’s), respiratory disease (Chronic Obstructive Pulmonary Disorders), and cardiology (Atherosclerosis, Coronary Heart Disease, Stroke & Peripheral Arterial Disease) across multi-regions and countries.
In addition to PM scope, her experiences in medical writing, regulatory submission, data management led her to become adaptable and cross-functional project manager.
Dr Yuanxi Xu,
Associate Medical Director
• Doctoral degree of Internal Medicine (Cardiovascular Diseases) from Tongji University; Attending physician of Cardiology
• 3 years of medical support in PPC (Medical monitoring & clinical pharmacology);
• 2 years as senior manager of DMPK in Shanghai Chempartner Co. Ltd.
• 3 years as clinical research scientist in Navona Biotech, Co., Ltd. MO, USA
• 4 years of research experience in Dept. of Cardiology, School of Medicine, University of Missouri-Columbia, MO, USA;
• Representative clinical trial areas: T2DM, autoimmune diseases (RA, AS, psoriasis), rare disease (PNH phase 1 and 2)